Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2005, the company has established itself as a leader in developing innovative treatments for central nervous system disorders, particularly epilepsy and attention deficit hyperactivity disorder (ADHD). With a strong focus on research and development, Supernus has launched several core products that stand out for their efficacy and safety profiles. The company’s commitment to addressing unmet medical needs has positioned it favourably in the market, earning recognition for its contributions to patient care. Supernus continues to expand its operational reach, with significant activities across North America, and remains dedicated to advancing therapeutic options that improve the quality of life for patients.
DitchCarbon Score
How does Supernus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Supernus Pharmaceuticals, Inc.'s score of 13 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Supernus Pharmaceuticals, Inc.'s reported carbon emissions
Supernus Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available data regarding its carbon emissions, including specific figures for Scope 1, 2, or 3 emissions. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This absence of data suggests that Supernus Pharmaceuticals may still be in the early stages of formalising its climate commitments or reporting on its environmental impact. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for Supernus to establish clear climate goals and transparency in emissions reporting to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Supernus Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
